Correcting the z~8 Galaxy Luminosity Function for Gravitational Lensing Magnification Bias

We present a Bayesian framework to account for the magnification bias from both strong and weak gravitational lensing in estimates of high-redshift galaxy luminosity functions. We illustrate our method by estimating the $z\sim8$ UV luminosity function using a sample of 97 Y-band dropouts (Lyman break galaxies) found in the Brightest of Reionizing Galaxies (BoRG) survey and from the literature. We find the luminosity function is well described by a Schechter function with characteristic magnitude of $M^\star = -19.85^{+0.30}_{-0.35}$, faint-end slope of $\alpha = -1.72^{+0.30}_{-0.29}$, and number density of $\log_{10} \Psi^\star [\textrm{Mpc}^{-3}] = -3.00^{+0.23}_{-0.31}$. These parameters are consistent within the uncertainties with those inferred from the same sample without accounting for the magnification bias, demonstrating that the effect is small for current surveys at $z\sim8$, and cannot account for the apparent overdensity of bright galaxies compared to a Schechter function found recently by Bowler et al. (2014a,b) and Finkelstein et al. (2014). We estimate that the probability of finding a strongly lensed $z\sim8$ source in our sample is in the range $\sim 3-15 \%$ depending on limiting magnitude. We identify one strongly-lensed candidate and three cases of intermediate lensing in BoRG (estimated magnification $\mu>1.4$) in addition to the previously known candidate group-scale strong lens. Using a range of theoretical luminosity functions we conclude that magnification bias will dominate wide field surveys -- such as those planned for the Euclid and WFIRST missions -- especially at $z>10$. Magnification bias will need to be accounted for in order to derive accurate estimates of high-redshift luminosity functions in these surveys and to distinguish between galaxy formation models.Comment: Accepted for publication in ApJ. 20 pages, 13 figure

High-contrast imager for Complex Aperture Telescopes (HiCAT): 1. Testbed design

Searching for nearby habitable worlds with direct imaging and spectroscopy will require a telescope large enough to provide angular resolution and sensitivity to planets around a significant sample of stars. Segmented telescopes are a compelling option to obtain such large apertures. However, these telescope designs have a complex geometry (central obstruction, support structures, segmentation) that makes high-contrast imaging more challenging. We are developing a new high-contrast imaging testbed at STScI to provide an integrated solution for wavefront control and starlight suppression on complex aperture geometries. We present our approach for the testbed optical design, which defines the surface requirements for each mirror to minimize the amplitude-induced errors from the propagation of out-of-pupil surfaces. Our approach guarantees that the testbed will not be limited by these Fresnel propagation effects, but only by the aperture geometry. This approach involves iterations between classical ray-tracing optical design optimization, and end-to-end Fresnel propagation with wavefront control (e.g. Electric Field Conjugation / Stroke Minimization). The construction of the testbed is planned to start in late Fall 2013.Comment: Proc. of the SPIE 8864, 10 pages, 3 figures, Techniques and Instrumentation for Detection of Exoplanets V

LONG-TERM IMMERSION TESTING OF ALLOY 22 AND TITANIUM GRADE 7 DOUBLE U-BEND SPECIMENS

ABSTRACT Double U-bend specimens of Alloy 22 (N06022) and Titanium Grade 7 (R52400) were exposed to a naturally aerated concentrated Basic Saturated Water (BSW) electrolyte at 105°C for over six years. Different type of discoloration of the Ti Gr 7 and Alloy 22 specimens was observed. General Corrosion was minimal and not distinguishable under a scanning electron microscope. None of the tested specimens suffered environmentally assisted cracking (EAC) or localized corrosion under the tested conditions. The specimens retained their residual stress after the long environmental exposure

Neurokinin B Receptor Antagonism in Women with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial

Context: Polycystic ovary syndrome (PCOS), the most common endocrinopathy in women, is characterized by high secretion levels of LH and T. Currently, there is no treatment licensed specifically for PCOS. Objective: The objective of this study was to investigate whether a targeted therapy would decrease LH pulse frequency in women with PCOS, subsequently reducing serum LH and T concentrations and thereby presenting a novel therapeutic approach to the management of PCOS. Design: This study is a double-blind, double-dummy, placebo-controlled, phase 2 trial. Settings: University hospitals and private clinical research centers were included. Participants: Women with PCOS aged 18–45 years participated. Intervention: Intervention included AZD4901 (a specific neurokinin-3 [NK3] receptor antagonist) at a dose of 20, 40, or 80 mg/day or matching placebo for 28 days. Main Outcome Measure: Change from baseline in the area under the LH serum concentration–time curve over 8 hours (area under the curve) on day 7 relative to placebo was measured. Results: Of a total 67 randomized patients, 65 were evaluable. On day 7, the following baseline-adjusted changes relative to placebo were observed in patients receiving AZD4901 80 mg/day: 1) a reduction of 52.0% (95% confidence interval [CI], 29.6–67.3%) in LH area under the curve; 2) a reduction of 28.7% (95% CI, 13.9–40.9%) in total T concentration; and 3) a reduction of 3.55 LH pulses/8 hours (95% CI, 2.0–5.1) (all nominal P &amp;lt; .05). Conclusions: The NK3 receptor antagonist AZD4901 specifically reduced LH pulse frequency and subsequently serum LH and T concentrations, thus presenting NK3 receptor antagonism as a potential approach to treating the central neuroendocrine pathophysiology of PCOS. </jats:sec

Multimode interferometry for entangling atoms in quantum networks

© 2019 IOP Publishing Ltd. We bring together a cavity-enhanced light-matter interface with a multimode interferometer (MMI) integrated onto a photonic chip and demonstrate the potential of such hybrid systems to tailor distributed entanglement in a quantum network. The MMI is operated with pairs of narrowband photons produced a priori deterministically from a single 87Rb atom strongly coupled to a high-finesse optical cavity. Non-classical coincidences between photon detection events show no loss of coherence when interfering pairs of these photons through the MMI in comparison to the two-photon visibility directly measured using Hong-Ou-Mandel interference on a beam splitter. This demonstrates the ability of integrated multimode circuits to mediate the entanglement of remote stationary nodes in a quantum network interlinked by photonic qubits

Does physical activity counselling enhance the effects of a pedometer-based intervention over the long-term : 12-month findings from the Walking for Wellbeing in the West study

Peer reviewedPublisher PD

Gait Impairment in Traumatic Brain Injury: A Systematic Review

Introduction: Gait impairment occurs across the spectrum of traumatic brain injury (TBI); from mild (mTBI) to moderate (modTBI), to severe (sevTBI). Recent evidence suggests that objective gait assessment may be a surrogate marker for neurological impairment such as TBI. However, the most optimal method of objective gait assessment is still not well understood due to previous reliance on subjective assessment approaches. The purpose of this review was to examine objective assessment of gait impairments across the spectrum of TBI. Methods: PubMed, AMED, OVID and CINAHL databases were searched with a search strategy containing key search terms for TBI and gait. Original research articles reporting gait outcomes in adults with TBI (mTBI, modTBI, sevTBI) were included. Results: 156 citations were identified from the search, of these, 13 studies met the initial criteria and were included into the review. The findings from the reviewed studies suggest that gait is impaired in mTBI, modTBI and sevTBI (in acute and chronic stages), but methodological limitations were evident within all studies. Inertial measurement units were most used to assess gait, with single-task, dual-task and obstacle crossing conditions used. No studies examined gait across the full spectrum of TBI and all studies differed in their gait assessment protocols. Recommendations for future studies are provided. Conclusion: Gait was found to be impaired in TBI within the reviewed studies regardless of severity level (mTBI, modTBI, sevTBI), but methodological limitations of studies (transparency and reproducibility) limit clinical application. Further research is required to establish a standardised gait assessment procedure to fully determine gait impairment across the spectrum of TBI with comprehensive outcomes and consistent protocols

Healthcare systems data in the context of clinical trials - A comparison of cardiovascular data from a clinical trial dataset with routinely collected data

BACKGROUND: Routinely-collected healthcare systems data (HSD) are proposed to improve the efficiency of clinical trials. A comparison was undertaken between cardiovascular (CVS) data from a clinical trial database with two HSD resources. METHODS: Protocol-defined and clinically reviewed CVS events (heart failure (HF), acute coronary syndrome (ACS), thromboembolic stroke, venous and arterial thromboembolism) were identified within the trial data. Data (using pre-specified codes) was obtained from NHS Hospital Episode Statistics (HES) and National Institute for Cardiovascular Outcomes Research (NICOR) HF and myocardial ischaemia audits for trial participants recruited in England between 2010 and 2018 who had provided consent. The primary comparison was trial data versus HES inpatient (APC) main diagnosis (Box-1). Correlations are presented with descriptive statistics and Venn diagrams. Reasons for non-correlation were explored. RESULTS: From 1200 eligible participants, 71 protocol-defined clinically reviewed CVS events were recorded in the trial database. 45 resulted in a hospital admission and therefore could have been recorded by either HES APC/ NICOR. Of these, 27/45 (60%) were recorded by HES inpatient (Box-1) with an additional 30 potential events also identified. HF and ACS were potentially recorded in all 3 datasets; trial data recorded 18, HES APC 29 and NICOR 24 events respectively. 12/18 (67%) of the HF/ACS events in the trial dataset were recorded by NICOR. CONCLUSION: Concordance between datasets was lower than anticipated and the HSD used could not straightforwardly replace current trial practices, nor directly identify protocol-defined CVS events. Further work is required to improve the quality of HSD and consider event definitions when designing clinical trials incorporating HSD